Literature DB >> 2162533

Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain.

R B Rothman1, V Bykov, B R de Costa, A E Jacobson, K C Rice, L S Brady.   

Abstract

Guinea pig brain membranes depleted of mu and delta receptors by pretreatment with the site-directed acylating agents, 2-(4-ethoxybenzyl)-1- diethylaminoethyl-5-isothiocyanatobenzimidazole.HCl (BIT) and N-phenyl-N-[1-(2-(4-isothiocyanato)phenethyl)-4- piperidinyl]-propanamide.HCl (FIT), were used in this study to test the hypothesis that guinea pig brain possesses subtypes of kappa receptors. Pretreatment of membranes with either (-)-(1S,2S)-U50,488 or the kappa selective acylating agent, (1S,2S)-trans-2-isothiocyanato-N-methyl-N-[2-(1- pyrrolidinyl)cyclohexyl]benzeneacetamide, caused a wash-resistant inhibition of kappa 1 binding sites labeled by [3H]U69,593 binding, but not kappa 2 binding sites labeled by [3H]bremazocine. Binding surface analysis of [3H]bremazocine binding resolved two binding sites, termed kappa 2 and kappa 2b, present at densities of 212 and 225 fmol/mg protein, which had low affinity for (-)-(1S,2S)-U50,488 and U69,593. The kappa 2b site had high affinity for beta-endorphin(1-31) (Kd = 5.5 nM) and [D-Ala2,D-Leu5]enkephalin (Kd = 14 nM), and lower affinity for [D-Ala2-MePhe4,Gly-ol5]enkephalin (Kd = 147 nM) and [Leu5]enkephalin (Kd = 46.0 nM). Binding surface analysis of [3H]U69,593 binding also resolved two binding sites, termed kappa 1a and kappa 1b, present at densities of 6.0 and 40.0 fmol/mg protein. The kappa 1a binding site was characterized by very high affinity for alpha-neoendorphin. Quantitative autoradiographic studies demonstrated that kappa 2a and kappa 2b binding sites are heterogeneously distributed in guinea pig brain, and that the anatomical distribution of kappa 1 binding sites reported in the literature is different from that observed in this study for the kappa 2 binding sites. Viewed collectively, these data provide evidence for four kappa receptor subtypes in guinea pig brain.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162533     DOI: 10.1016/0196-9781(90)90088-m

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  24 in total

Review 1.  Peripheral kappa-opioid agonists for visceral pain.

Authors:  Pierre J-M Rivière
Journal:  Br J Pharmacol       Date:  2004-03-29       Impact factor: 8.739

Review 2.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

3.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 4.  The presence of endogenous morphine signaling in animals.

Authors:  George B Stefano; Patrick Cadet; Richard M Kream; Wei Zhu
Journal:  Neurochem Res       Date:  2008-09-06       Impact factor: 3.996

5.  Synthesis and pharmacology of halogenated δ-opioid-selective [d-Ala(2)]deltorphin II peptide analogues.

Authors:  Robyn Pescatore; Gina F Marrone; Seth Sedberry; Daniel Vinton; Netanel Finkelstein; Yitzchak E Katlowitz; Gavril W Pasternak; Krista R Wilson; Susruta Majumdar
Journal:  ACS Chem Neurosci       Date:  2015-04-14       Impact factor: 4.418

6.  Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay.

Authors:  J H Broadbear; S S Negus; E R Butelman; B R de Costa; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1994-07       Impact factor: 4.530

7.  Studies of the biogenic amine transporters. 1. Dopamine reuptake blockers inhibit [3H]mazindol binding to the dopamine transporter by a competitive mechanism: preliminary evidence for different binding domains.

Authors:  C M Dersch; H C Akunne; J S Partilla; G U Char; B R de Costa; K C Rice; F I Carroll; R B Rothman
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

8.  Immunomodulatory activity of mu- and kappa-selective opioid agonists.

Authors:  D D Taub; T K Eisenstein; E B Geller; M W Adler; T J Rogers
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

Review 9.  Endogenous morphine/nitric oxide-coupled regulation of cellular physiology and gene expression: implications for cancer biology.

Authors:  George B Stefano; Richard M Kream; Kirk J Mantione; Melinda Sheehan; Patrick Cadet; Wei Zhu; Thomas V Bilfinger; Tobias Esch
Journal:  Semin Cancer Biol       Date:  2007-12-08       Impact factor: 15.707

10.  Guanine nucleotide-binding protein-coupled and -uncoupled states of opioid receptors and their relevance to the determination of subtypes.

Authors:  A Richardson; C Demoliou-Mason; E A Barnard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.